Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for hepatitis C after organ transplantation -Pilot Study-

Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for hepatitis C after organ transplantation -Pilot Study- - Interferon-free therapy for posttransplant hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016558

Enrollment

Registered

2015-02-16

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis C after transplantation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hepatitis C after organ transplantation 2. HCV genotype 1 3. 20 years old and over 4. Written informed consent for participation in this study is obtained

Exclusion criteria

Exclusion criteria: without abilty to understand informed consent

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of antiviral therapy with dacltasvir and asunaprevir for hepatitis C after organ transplantation	—

Countries

Japan

Contacts

Public ContactKentaro Ide

Hiroshima University Hospital Trasnplantation surgery

ideken@hiroshima-u.ac.jp082-257-5222

Outcome results